Leiomyosarcoma of the urinary bladder in adult patients: A systematic review of the literature and meta-analysis

Revision 1, Ms. No. 201803023

Helen Zieschang[1], Rainer Koch[2], Manfred P. Wirth[1], Michael Froehner[1],

Departments of [1]Urology and [2]Medical Informatics and Biometry, University Hospital "Carl Gustav Carus", Technische Universität Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany.

Corresponding author:

Helen Zieschang
Department of Urology
University Hospital Carl Gustav Carus
Technische Universität Dresden
Fetscherstrasse 74
D-01304 Dresden, Germany
Phone: +49-351-4582447
Fax: +49-351-4584333
E-mail: helenz@hotmail.de

Conflict of Interest statement: The authors declare no conflicts of interest.

Word count: text: 1574 (excluding abstract: 291), 2 figures, 2 tables, 85 references.

Key words: urological neoplasms; bladder; sarcoma; leiomyosarcoma; systematic review of the literature; meta-analysis; treatment; mortality.

Abstract

Purpose: Leiomyosarcoma of the urinary bladder is exceedingly rare. Most clinicians see only few cases during their career and information regarding treatment and outcome is scattered in the scientific literature. Interested clinicians and patients have to undertake troublesome search for treatment and outcome information.

Material and methods: We performed a systematic review of the literature using the PubMed and Web of Science databases and included all identified cases published in English language between 1970 and June 2018 into a meta-analysis. Prior to the literature search, key questions were formulated which should be tried to answer with the data obtained.

Results: We analyzed clinical data of 210 cases of urinary bladder leiomyosarcoma revealed by this review and seen in our institution. The mean age of patients was 52 years. The majority (75%) of the tumors was classified as high grade sarcomas. We found no report of a prior radiation therapy to the pelvic organs, but some authors suggested an association between cyclophosphamide treatment and the development of bladder leiomyosarcoma, especially in patients with retinoblastoma. For the whole sample, we determined 5-year and 10-year cancer-specific cumulative mortality rates of 38% and 50%. Patients with high grade sarcomas had a trend towards a higher mortality compared with low grade tumors (p=0.0280). The most promising treatment option seems to be surgery (radical or partial cystectomy) with negative resection margins, possibly supplemented by chemotherapy or radiation.

Conclusion: About half of patients with bladder leiomyosarcoma survived on the long run. Low grade tumors may have a better outcome with, nevertheless, countable long-term mortality. For a better assessment of that rare bladder tumor, its best treatment options and the influence of neoadjuvant or adjuvant therapies on the outcome of patients, larger series with long-term survival data are required.

Introduction

Non-urothelial neoplasms rarely occur in the urinary bladder. Leiomyosarcoma represents the most common subtype of malignant mesenchymal tumors in this organ, but still accounts for less than 1% of all primary bladder tumors [1]. Until now, knowledge about this rare disease comes mainly from individual case reports or smaller case series and there is only little information about long-term survival rates. The published largest series was a Surveillance, Epidemiology, and End Results database study enrolling 183 patients treated between 1973 and 2010 [1]. In our study, we performed a systematic review of the literature with meta-analysis of reported cases with sufficient data in order to give clinicians and patients a rapid overview on the knowledge about this rare disease.

Material and methods

The PubMed and Web of Science databases were used to perform a systematic literature review, based on the criteria described by Galfano and Novara [2]. With the key words “leiomyosarcoma” and ”bladder”, 386 articles could be retrieved on the PubMed and 232 items on the Web of Science database on June 08, 2018. We only considered articles in English language that were published between 1970 and June 2018. Patients with a primary urinary bladder leiomyosarcoma and a minimum age of 16 years were included. We identified 209 published cases and added one unpublished case seen in our institution. Detailed characteristics about all these cases are summarized in a supplementary table [3-81]. In some larger series, it was not possible to assign clinical information to each patient [1,57,60,82]. However, when

survival details were given for individual cases [57,60], they were included into the statistical analysis.

The follow-up information of two patients seen in our clinic and published earlier [39] was updated. The following key questions were formulated prior to literature search in order to be answered with the data obtained by this review: (1) predisposing factors for the development of bladder sarcomas; (2) mean age of patients at the time of diagnosis; (3) proportion of primary surgical treatment; (4) sites and time of tumor recurrence; (5) 5-year and 10-year cumulative mortality rates of high grade versus low grade tumors. The statistical analysis was performed with the Statistical Analysis Systems (SAS Institute Inc., Cary, North Carolina, USA), using competing risk analyses to determine cumulative disease-specific mortality rates and Pepe-Mori tests to compare the mortality curves. All stated percentages are based on the number of articles with existent information about the specific topics, articles with unknown information were not considered.

Results

Overall, 210 cases with data suitable for statistical analysis were identified. 58% of the tumors occurred in males. Age at diagnosis ranged from 16 to 88 years, with a mean age of 52 years. Data on symptoms was available in 91/210 cases (43%). Painless hematuria was the most frequently reported symptom (80%), less common symptoms included dysuria, nocturia, obstructive symptoms, increased frequency of micturition, pelvic and abdominal pain, urinary retention or recurrent urinary tract infections. The sarcomas had a mean size of 6 cm (range 0.5 to 16 cm) and 75% were classified as high grade tumors. None of the patients had a history of radiation therapy of the pelvic organs, but there were seven cases with radiation of the head and neck region for

Hodgkin's or non-Hodgkin's lymphomas and retinoblastomas. 14 patients suffered from retinoblastoma in childhood, 9 of them had received a chemotherapy including cyclophosphamide. Altogether, 5 patients had a cyclophosphamide therapy for other diseases. Further, the occurrence of bladder leiomyosarcomas was described for one patient with schistosomiasis, one with a long-term tamoxifen therapy and one with chronic ketamine abuse. Metastases were mentioned in only 4 cases (2%) at the time of diagnosis, twice in the lymph nodes and twice with unknown site. 78% (n=120) of the patients with information about therapy (n=153) underwent primarily surgical treatment (radical cystectomy in 66/153 (43%), partial cystectomy in 54 cases (35%)). 26% (31/120) of the patients with surgical treatment received a neoadjuvant or adjuvant radiation or chemotherapy in addition to surgery**.** A total of 26 patients had a transurethral resection of the bladder tumor only with no further reported surgical procedure.

Chemotherapy or radiation was the only treatment for 9 patients. In 55 cases, complete resection with negative surgical margin status was reported. Tumor recurrence was observed in 53/210 patients (25%), predominantly locally in the pelvis (18/53 recurrences, 34%) and within the first 3 years after therapy. Distant metastases were mainly located in the lung, liver or bones. Only two late recurrences were reported (8 and 12 years after diagnosis, respectively [31,53]). The longest documented follow-ups of bladder leiomyosarcoma patients were 20 years after a radical cystectomy [22] and narrowly 22 years after a partial cystectomy [39, updated follow-up]. Disease-specific cumulative mortality rate was 18% after one year, 38% after 5 years and 50% after 10 years for all leiomyosarcoma patients (figure 1, table 1). Compared with patients with high grade tumors (n=95), those with low grade tumors (n=32) had a lower mortality rate (figure 2, table 1). Disease-specific cumulative mortality rates were

58% and 69% after 5 and 10 years for high grade sarcomas, 7% and 27% for low grade sarcomas.

Discussion

With this systematic literature review of all reported cases of urinary bladder leiomyosarcomas since 1970, we were able to analyze the clinical features and survival data of 209 published case reports and one added unpublished case seen at our department. It has to be considered that the extent of information varied among the articles and completeness of data could not be achieved. Only the 127 cases with information about tumor grading could be used for the statistical comparison of high grade and low grade sarcomas (figure 2). Repeatedly, an association between cyclophosphamide treatment and the development of bladder leiomyosarcoma was observed (14 cases). It has been hypothesized that such treatment especially in patients with a genetic retinoblastoma could be a risk factor for this rare bladder tumor [83]. We did not find a case with a prior radiation to the pelvic organs, but to the head and neck region for lymphomas and retinoblastomas suggesting that local radiotherapy plays no major role in the pathogenesis of bladder leiomyosarcoma. A schistosomiasis of the urinary bladder as a documented risk factor for the development of bladder tumors was observed in one patient [20,84]. The reviewed sarcomas were diagnosed at a median age of 52 years, with a male to female ratio of 1.4:1. The frequently used primary treatment was surgery, with radical cystectomy being the most common procedure, followed by partial cystectomy, which can be adequate for smaller tumors. Spiess and co-workers reported a series of 19 bladder sarcoma patients (mainly leiomyosarcomas) and showed an association between the surgical margin status and the recurrence-free, disease-specific and overall survival. They revealed a 5-year

disease-specific survival rate of 59%, which is very close to our results [85]. In our study, we determined 5-year and 10-year disease-specific cumulative mortality rates of 38% and 50% for all reviewed bladder leiomyosarcoma patients, 58% and 69% for patients with a high grade sarcoma and 7% and 27% for low grade tumors. Rosser and co-workers documented a 5-year disease-specific survival rate of 62% in a series of 36 high grade bladder leiomyosarcomas that were mainly treated with radical cystectomy, frequently combined with neoadjuvant or adjuvant chemotherapy. Doxorubicin and ifosfamide were the most commonly used regime. The authors described downstaging in all four patients with metastatic disease that received neoadjuvant chemotherapy [82]. We did not identify a case of complete response achieved by chemotherapy alone, but in one case treated by radiation following chemotherapy for a low grade leiomyosarcoma [68] suggesting that multimodal treatment could be beneficial in individual cases of advanced disease. Rodríguez and co-workers published the largest series of bladder leiomyosarcoma patients so far. They reported 5-year and 10-year cancer-specific survival rates of 47% and 35% for 183 patients detected with the Surveillance, Epidemiology and End Results (SEER) database. Moreover, they showed that an undifferentiated tumor grade, distant disease and the absence of surgical treatment were associated with a worse outcome [1]. In comparison to our study, they revealed lower cancer-specific survival rates, which may be caused by a higher median age of patients (65 vs. 52 years) or the higher proportion of distant disease at the time of diagnosis (10% vs. 2%). A total of 25% of the patients in our meta-analysis experienced a tumor relapse, which mainly occurred in the pelvis as a local recurrence and within the first three years after primary treatment. The lung, liver and bones were common sites for distant metastases. Diagnostic workup should focus on these sites.

This study has several limitations. The information that was obtainable from the analyzed case series and single case reports was partially incomplete and the follow-up was limited. It may not be ruled out that there was some publication bias with a preferred reporting of unusual cases and/or cases with apparently successful treatment. Because of the long time period considered with the literature search, it is conceivable that current classification standards would change the histopathological classification of some tumors.

Conclusion

Leiomyosarcoma of the urinary bladder commonly presents as a high grade tumor. We determined 5-year and 10-year cancer-specific cumulative mortality rates of 38% and 50% in this systematic review and meta-analysis of 210 cases. The most important treatment option seems to be surgical resection (radical or partial cystectomy) with negative margins. Surgery can be supplemented by chemotherapy or radiation, especially for metastatic disease or to achieve resectability.

References

[1] Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS. Clinical features of leiomyosarcoma of the urinary bladder: Analysis of 183 cases. Urol Oncol 2014;32:958-65.

[2] Galfano A, Novara G. Methodological bases for systematic reviews. J Androl Sci 2008;15:185-193.

[3] Tara HH, Mentus NL. Leiomyosarcoma of urinary bladder. Urology 1973;2:460-2.

[4] Narayana AS, Kelly DG, Duff FA. Leukaemoid reaction in a case of leiomyosarcoma of the bladder. Postgrad Med J 1977;53:766-8.

[5] Poleksic S. Leiomyosarcoma of urinary bladder in von Recklinghausen's neurofibromatosis. Urology 1977;10:341-2.

[6] Ananthakrishnan N, Hariharan S, Shankar SK, Kapur BM. Pedunculated leiomyosarcoma of urinary bladder of unusual size. Indian J Cancer 1978;15:72-4.

[7] Narayana AS, Loening S, Weimar GW, Culp DA. Sarcoma of the bladder and prostate. J Urol 1978;119:72-6.

[8] Papacharalambous AN, Pavlakis AJ. Leiomyosarcoma of the bladder. Br J Urol 1979;51:321.

[9] Wilson TM, Fauver HE, Weigel JW. Leiomyosarcoma of urinary bladder. Urology 1979;13:565-7.

[10] Savir A, Meiraz D. Malignant mesodermal (mesenchymal) tumors of bladder. Urology 1980;16:307-9.

[11] Alabaster AM, Jordan WP Jr, Soloway MS, Shippel RM, Young JM. Leiomyosarcoma of the bladder and subsequent urethral recurrence. J Urol 1981;125:583-5.

[12] Patterson DE, Barrett DM. Leiomyosarcoma of urinary bladder. Urology 1983;21:367-9.

[13] Rowland RG, Eble JN. Bladder leiomyosarcoma and pelvic fibroblastic tumor following cyclophosphamide therapy. J Urol 1983;130:344-6.

[14] Seo IS, Clark SA, McGovern FD, Clark DL, Johnson EH. Leiomyosarcoma of the urinary bladder. 13 years after cyclophosphamide therapy for Hodgkin's disease. Cancer 1985;55:1597-603.

[15] Sen SE, Malek RS, Farrow GM, Lieber MM. Sarcoma and carcinosarcoma of the bladder in adults. J Urol 1985;133:29-30.

[16] Swartz DA, Johnson DE, Ayala AG, Watkins DL. Bladder leiomyosarcoma: a review of 10 cases with 5-year followup. J Urol 1985;133:200-2.

[17] Chen KT. Coexisting leiomyosarcoma and transitional cell carcinoma of the urinary bladder. J Surg Oncol 1986;33:36-7.

[18] Young RH, Proppe KH, Dickersin GR, Scully RE. Myxoid leiomyosarcoma of the urinary bladder. Arch Pathol Lab Med 1987;111:359-62.

[19] Ahlering TE, Weintraub P, Skinner DG. Management of adult sarcomas of the bladder and prostate. J Urol 1988;140:1397-9.

[20] Alwan MH, Sayed M, Kamal MM. Schistosomiasis and sarcoma of the urinary bladder. Eur Urol 1988;15:139-40.

[21] Gaboardi F, Bordinazzo R, Bersiga A, Galli L. Nd: YAG laser treatment of vesical leiomyosarcoma. Arch Esp Urol 1989;42:288-9.

[22] Mills SE, Bova GS, Wick MR, Young RH. Leiomyosarcoma of the urinary bladder. A clinicopathologic and immunohistochemical study of 15 cases. Am J Surg Pathol 1989;13:480-9.

[23] Giustacchini M, Menchinelli P, Vincenzoni A, D'Addessi A, Alcini F. Bladder leiomyosarcoma: a case report. Acta Medica Romana 1990;28:130-5.

[24] Thrasher JB, Miller GJ, Wettlaufer JN. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 1990;143:119-21.

[25] Van Thillo EL, Casselman J, Defloor E. Leiomyosarcoma of urinary bladder. Acta Urol Belg 1991;59:113-8.

[26] Caspi B, Weinberg D, Weissman A, Eisencraft S, Dgani R. Leiomyosarcoma of the bladder - ultrasonographic features. Ultrasound Obstet Gynecol 1992;2:432-3.

[27] Özteke O, Demirel A, Aydin NE, Memiş L. Bladder leiomyosarcoma: report of three cases. Int Urol Nephrol 1992;24:393-6.

[28] Russo P, Brady MS, Conlon K, Hajdu SI, Fair WR, Herr HW, Brennan MF. Adult urological sarcoma. J Urol 1992;147:1032-7.

[29] Chakravorty S, Venugopal N, Kamath MG, Venugopal P. Leiomyosarcoma of urinary bladder: a case report. Indian J Pathol Microbiol 1993;36:292-4.

[30] Kawamura J, Sakurai M, Tsukamoto K, Tochigi H. Leiomyosarcoma of the bladder eighteen years after cyclophosphamide therapy for retinoblastoma. Urol Int 1993;51:49-53.

[31] Kunze E, Theuring F, Krüger G. Primary mesenchymal tumors of the urinary bladder. A histological and immunohistochemical study of 30 cases. Pathol Res Pract 1994;190:311-32.

[32] Angulo JC, Sakr W, Olford J, Montie JE, Grignon DJ. Multifocal leiomyosarcoma of the urinary bladder. J Urol Pathol 1995;3:377-384.

[33] Pedersen-Bjergaard J, Jonsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol 1995;13:532–3.

[34] De Berardinis E, Giulianelli R, Zarrelli G, De Santis C, Ginepri A, Gentile BC, Di Silverio F. Leiomyosarcoma of urinary bladder: personal experience in 3 cases over a 10-year period. Arch Ital Urol Androl 1997;69:73-80.

[35] Lei KI, Gwi E, Ma L, Liang EY, Johnson PJ. 'Spontaneous' regression of advanced leiomyosarcoma of the urinary bladder. Oncology 1997;54:19-22.

[36] Proulx GM, Gibbs JF, Lee RJ, Velagapudi S, Huben R. Sarcoma of the bladder: a case report with review of the literature. Radiol Oncol 1999;33:63-8.

[37] Spitz A, Stein JP, Lieskovsky G, Skinner DG. Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy: a new technique. J Urol 1999;161:1761-4.

[38] Videtic GM, Venkatesan VM. Hyperbaric oxygen corrects sacral plexopathy due to osteoradionecrosis appearing 15 years after pelvic irradiation. Clin Oncol 1999;11:198-9.

[39] Froehner M, Lossnitzer A, Manseck A, Koch R, Noack B, Wirth MP. Favorable long-term outcome in adult genitourinary low-grade sarcoma. Urology 2000;56:373-7.

[40] Tan KY, Yip SK, Tan PH. Clinics in diagnostic imaging (50). Leiomyosarcoma of bladder. Singapore Med J 2000;41:301-4.

[41] Liang SX, Lakshmanan Y, Woda BA, Jiang Z. A high-grade primary leiomyosarcoma of the bladder in a survivor of retinoblastoma. Arch Pathol Lab Med 2001;125:1231-4.

[42] Motta L, Porcaro AB, Ficarra V, D'Amico A, Piubello Q, Comunale L. Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma. Scand J Urol Nephrol 2001;35:248-9.

[43] Watanabe K, Baba K, Saito A, Hoshi N, Suzuki T. Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract. Arch Pathol Lab Med 2001;125:1070-3.

[44] Martin SA, Sears DL, Sebo TJ, Lohse CM, Cheville JC. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma. Am J Surg Pathol 2002;26:292-300.

[45] Parekh DJ, Jung C, O'Conner J, Dutta S, Smith ER Jr. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology 2002;60:164.

[46] Bléoo SL, Godbout R, Rayner D, Tamimi Y, Moore RB. Leiomyosarcoma of the bladder in a retinoblastoma patient. Urol Int 2003;71:118-21.

[47] Tanguay C, Harvey I, Houde M, Srigley JR, Têtu B. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003;16:512-4.

[48] Venkatraman L, Goepel JR, Steele K, Dobbs SP, Lyness RW, McCluggage WG. Soft tissue, pelvic, and urinary bladder leiomyosarcoma as second neoplasm following hereditary retinoblastoma. J Clin Pathol 2003;56:233-6.

[49] Gopalakrishnan K, Pai RR, Kini H, Prabhu GG. Leiomyosarcoma of the urinary bladder: a case report. Indian J Pathol Microbiol 2004;47:58-9.

[50] Hemachandran M, Nada R, Rajwanshi A. Leiomyosarcoma of the urinary bladder: a diagnostic challenge in urine cytology. Diagn Cytopathol 2004;31:281-2.

[51] Richter ER, Dean RC. Leiomyosarcoma of the urinary bladder in a teenage male. Mil Med 2004;169:155-6.

[52] Al-Zahrani AA, Kamal BA, Eldarawani HM, Hashim TM. Leiomyosarcoma of the bladder in a 16-year-old girl with a history of cyclophosphamide therapy for bilateral retinoblastoma during infancy. Saudi Med J 2006;27:531-3.

[53] Brucker B, Ernst L, Meadows A, Zderic S. A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy. Pediatr Blood Cancer 2006;46:811-4.

[54] Sawhney R, Curry N, Burks T, Chaudhary UB. Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel. Anticancer Drugs 2007;18:745-7.

[55] Bakaris S, Resim S, Tasci AI, Demirpolat G. A rare case of synchronous leiomyosarcoma and urothelial cancer of the bladder. Can J Urol 2008;15:3920-3.

[56] Labanaris AP, Zugor V, Meyer B, Scheuering S, Takriti S, Kuhn R. A rare case of urinary bladder leiomyosarcoma accompanied by prostate cancer. Can J Urol 2008 b;15:4009-11.

[57] Labanaris AP, Zugor V, Meyer B, Nützel R, Helmus S, Labanaris PG, Kühn R. Urinary bladder leiomyosarcoma in adults. Int Urol Nephrol 2008 a;40:311-6.

[58] Minagawa T, Okaneya T, Kamigaito M, Nishizawa S, Ogawa T, Kawakami M, Nakayama T, Imamura T, Kato H, Nishizawa O. Leiomyosarcoma of the urinary bladder in a patient with bilateral retinoblastoma. Int J Urol 2008;15:548-50.

[59] Lee TK, Miyamoto H, Osunkoya AO, Guo CC, Weiss SW, Epstein JI. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases. Am J Surg Pathol 2010;34:502-9.

[60] Lindberg MR, Fisher C, Thway K, Cao D, Cheville JC, Folpe AL. Leiomyosarcoma of the urinary bladder: a clinicopathological study of 34 cases. J Clin Pathol 2010;63:708-13.

[61] Nelius T, Stevens J, Samathanam C, Filleur S. Leiomyosarcoma of the urinary bladder presenting as life threatening gross hematuria. Med Oncol 2010;27:562-7.

[62] Ricciardi E, Maniglio P, Schimberni M, Moscarini M. A case of high-grade leiomyosarcoma of the bladder with delayed onset and very poor prognosis. World J Surg Oncol 2010;8:16.

[63] Xu YF, Wang GC, Zheng JH, Peng B. Partial cystectomy: Is it a reliable option for the treatment of bladder leiomyosarcoma? Can Urol Assoc J 2011;5:E11-3.

[64] Yamada T, Nagai S, Kanimoto Y. Rapid progression of a urinary bladder leiomyosarcoma: report of a case. Case Rep Urol 2011;2011:532081.

[65] Svajdler M Jr, Andrašina I, Ilenčíková D, Rychlý B, Piačková B. Recurring multifocal leiomyosarcoma of the urinary bladder 22 years after therapy for bilateral (hereditary) retinoblastoma: a case report and review of the literature. Cesk Patol 2012;48:44-8.

[66] Barry L, Baxter G, Pitchamuthu H, Crooks JE, Rajan P, Ahmad I. Aggressive bladder leiomyosarcoma in a patient receiving tamoxifen therapy. J Clin Urol 2013;6:327-329.

[67] Froehner M, Schober RR, Koch R, Lossnitzer A, Laniado M, Wirth MP. Adult urologic sarcoma: experience during 2 decades. Urol Oncol 2013;31:985-9.

[68] Gupta DK, Singh V, Sinha RJ, Kumar V, Nagathan DS, Sankhwar SN. Leiomyosarcoma, a nonurothelial bladder tumor: a rare entity with therapeutic diversity. Korean J Urol 2013;54:409-11.

[69] Hamadalla NY, Rifat UN, Safi KC, Mohammed M, Abu-Farsakh H. Leiomyosarcoma of the urinary bladder: A review and a report of two further cases. Arab J Urol 2013;11:159–164.

[70] Makis W, Rakheja R, Nahal A, Hickeson M, Lisbona R. Urinary bladder leiomyosarcoma: staging with 18F-FDG PET/CT. Clin Nucl Med 2013;38:e218-22.

[71] Doddamani SC, Bhat S, Jacob A. Urinary bladder leiomyosarcoma following radiotherapy in a patient with bilateral retinoblastoma: A case report. Indian J Urol 2015;31:366-8.

[72] Patnayak R, Jena A, Rambabu S, Reddy MK. Leiomyosarcoma of urinary bladder-potential mimicker of carcinoma: Case report and short review of literature. Indian J Cancer 2015;52:573-4.

[73] Ramírez Sevilla C, Admella-Salvador C, Romero-Martin JA, Llopis-Manzanera J, Barranco-Sanz MA. Bladder leiomyosarcoma 25 years after treatment with cyclophosphamide in patient with history of retinoblastoma. Urol Int 2015. [Epub ahead of print]

[74] Zhong D, Yu F, Chen J, Lin C, Luo H. Bladder leiomyosarcoma in a patient with chronic ketamine abuse: A case report. Can Urol Assoc J 2015;9:E514-6.

[75] Fakhoury M, Hwang RR, Silletti J, Bjurlin MA. Bladder leiomyosarcoma: A rare, but aggressive diagnosis. Curr Urol 2016;9:166-168.

[76] Jain N, Shirazi N, Chauhan N, Gupta M. Unusual Visceral Sarcomas: Report of 2 Cases with Review of Literature. J Clin Diagn Res 2016;10:ED14-ED16.

[77] Ribeiro JG, Klojda CA, Araújo CP, Pires LA, Babinski MA. Giant leiomyosarcoma of the urinary bladder. J Clin Diagn Res 2016;10:PD14-5.

[78] Mitra S, Kaur G, Kakkar N, Singh P, Dey P. Sarcoma in urine cytology; an extremely rare entity: A report of two cases. J Cytol 2017;34:171-173.

[79] Anastasiou A, Katafigiotis I, Skoufias S, Anastasiou I, Constantinides C. Conservative management of a bladder leiomyosarcoma in a 43-year-old patient. Arch Ital Urol Androl 2018;90:70-71.

[80] Jayarajah U, Fernando MH, Herath KB, de Silva VC, Goonewardena SAS. Partial cystectomy for a primary locally advanced leiomyosarcoma of the bladder: a case report and review of the literature. Clin Case Rep 2018;6:883-886.

[81] Menon AR, Puthalath RT, Suresh N, Hegde S. Organ preservation in leiomyosarcoma bladder: Case report and review of literature. Urol Ann 2018;10:233-236.

[82] Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology 2003;61:1151-5.

[83] Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661–671.

[84] Honeycutt J, Hammam O, Fu CL, Hsieh MH. Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. Trends Parasitol 2014;30:324-32.

[85] Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 2007;25:38-45.

Table 1: Disease-specific cumulative mortality rates for the whole sample and separately for low grade versus high grade leiomyosarcoma patients after 1, 5 and 10 years with 95% confidence interval and numbers of patients at risk at these time points. Data obtained by systematic review of the literature.

Figure 1: Cumulative disease-specific mortality rate in the whole sample of tumors with follow-up data allowing meta-analysis (n=210).

Figure 2: Cumulative disease-specific mortality rate of high grade (n=95) vs. low grade tumors (n=32), p=0.0280. Grading was not available in 83 cases.